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Abstract
BACKGROUND: The prevalence of overactive bladder (OAB) appears to increase with age (aging), and free radicals 
most contribute to an increase in the aging process. But now, some researchers have found the efficacy of Morinda 
citrifolia in inhibiting the oxidative stress process so that it is expected to be beneficial for the treatment of OAB.
AIM: The aim of this study was to find out the effect of M. citrifolia extract on overactive women bladder (OAB) 
through observation of high-sensitivity C-reactive protein (hs-CRP) urine level.
METHODS: This research is an experimental study using double-blind randomized controlled trial design conducted 
at General Hospital H. Adam Malik Medan, USU Pharmacy Laboratory for extraction of noni fruit (M. citrifolia) and 
the Integrated Laboratory of Biochemical-Biomolecular USU Faculty of Medicine for the examination of hs-CRP 
urine levels. A t-dependent test is performed if data distribution is normally distributed or if not normally distributed, 
the median values are compared with the Mann–Whitney U-test. The effect of noni in hs-CRP levels performed by 
wilcoxon signed-Ranks Test. The statistical significance test with CI 95% and significant difference value p<0,05.
RESULTS: These results indicate that the noni fruit extract has weak antioxidant activity (IC50 >150 ppm). From the 
statistical analysis, a significant difference (p < 0.05) was obtained in hs-CRP urine level after compared to before 
treatment. These results indicate that after treatment, there was an improvement in the degree of OAB symptom 
scores in Group A and Group B.
CONCLUSIONS: Noni fruit extract (M. citrifolia) is proven to be able to inhibit oxidative stress in urothelium through 
observation of hs-CRP urine levels in overactive women bladder (OAB).
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Introduction
Overactive bladder (OAB) is one of the lower 
urinary tract syndrome with clinical symptom urgency, 
frequency, and nocturia, which is one of the condition 
cause health problem both in men and woman, 
especially in older people [1]. OAB clinical syndrome 
by overactivating detrusor muscle which it will over 
contracted the bladder. According to the International 
Continence Society, OAB is defined as clinical syndrome 
contains of urgency with or without incontinence and 
frequency, nocturia, with or without urinary infection 
or other pathology in the bladder. A systemic review 
by Milsom et al. showed that among 16.776 person 
frequency and urgency are the most clinical symptom 
found in patients (85% and 54%, respectively) [2].
Vignoli said, the prevalence of OAB is about 
16% in all population men and women, but it was 
increasingly happened in woman with age older than 40 
years old [3]. Noble shows increasing urge incontinence 
in woman over 44 years old 2–19% and man over than 
64 years old 0.3–9%. OAB with incontinence in woman 
was 9.3% and OAB without incontinence 7.6% [4]. 
According to Chapple et al. [5]. OAB Prevalence about 
20% worldwide in China about 23.9% in South Korea 
22.1% and in Taiwan 19.7% which is more effected in 
woman than men and the prevalence getting higher in 
older people 27.9% >60 years old [6].
The risk factor that affects OAB is increasing 
age, differentiation of gender, obesity, lifestyle, 
socioeconomic, and history of pregnancy and operation. 
Increment in age causes OAB because there are 
degradating cells and molecular system of the vascular, 
dysfunction and hyper-permeability vascular and brain, 
increasing of stress oxidative, and inflammation [7].
Bladder inflammation is anticipated by sensory 
nerve neuroplasticity so that there are an increase in 
nerve growth factor (NGF) levels in the urine, thus acting 
as a biomarker in the pathogenesis of OAB [8]. Bladder 
inflammation also stimulates serum C-reactive protein 
(CRP) levels in OAB men and women and results in a 
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significant increase in serum CRP levels in patients with 
wet OAB (2.96 ± 0.47 vs. 0.93 ± 0.27 mg/L, p < 0.01) 
and dry OAB (2.96 ± 0.47 vs. 1.06 ± 0.16 mg/L, p < 
0.05), as compared to normal individuals [9].
Bladder overactivity is more often in woman 
than men because the hormonal system in the 
neurotransmitter of hydroxytryptamine (5-HT) in the 
central nervous system leads to decreasing inhibition 
of micturition can cause OAB [10].
Obesity leads to OAB because increasing 
pressure of the abdomen increasing pressure of 
bladder cause urgency and frequency. Lifestyle factor 
alcoholic woman, tea, and coffee consumer will have a 
risk of OAB. Smoking is one of the risk factor of OAB. 
Incidences of LUTS in America, there are 27% Asian 
women, has OAB 43% in white people, 46% in African-
American women, and 42% Latin America. A history of 
pregnancy woman which has previous spontaneous 
vaginal delivery predicted has OAB 4 times than normal 
woman [11].
Diagnostic procedure to OAB by history taking 
looking for symptoms of urgency, frequency, and 
nocturia. Laboratory test for urinalysis to detect urinary 
tract infection (UTI). Cystoscopy to exclude other blader 
abnormalities such as diverticulae, bladder stone, 
interstitial cystitis, urethral stricture, and obstruction 
of the bladder outlet. urodynamic procedure to assest 
detrusor overactivity [12].
Biomarker for OAB, one of theory of OAB 
is nerve inflammation that related to overexpression 
calcitonin gene-related peptide, substance P, brain 
derived neurotropic factor, NGF, CRP, prostaglandin 
(PG), adenosine triphosphate, and nitric oxide (NO) [13].
CRP is one the leading protein as an 
inflammation marker activites the ligand will increas 
opsonization. CRP trigger syntetic of interleukin 
(IL)-1, tumor necrosis factor-α (TNF-α), and IL-6 on 
mononuclear peripheral vascular. In some study relation 
CRP and OAB on Boston Area Community Health, there 
are increasing levels of CRP serum and increasing 
odds from OAB patient. Increasing CRP level 1.83 ± 
2.30 mg/L, this data support hypothesis inflammation 
process in the bladder as pathogenesis in OAB [14].
Noni fruit (Morinda citrifolia) a plant which is 
grow in torpical zone such as Africa, South America, 
Caribia, Australia, New Zealand, Pacific islands, China, 
Mlaysia, Indonesia, and India. This plant has many 
advantages from its root, trunk, and also the fruit. 
Noni fruit is administered in the Indonesian formulary 
that has security proof, and the benefits have proven 
empirically. Srinivasan research antioxidant enzyme 
from noni fruit extract is superoxide dismutase 12.74 
± 0.27 U/g, catalase 73.08 ± 3.01 U/g, glutathione 
reductase 12.37 ± 0.33 U/g, glutathione peroxidase 
36.94 ± 2.13 U/g and glutathione s-transferase 7.21 ± 
0.17 U/g, ascorbic acid 23.6 ± 1.0 mg/g, α-tocopherol 
83.5 ± 0.5 mg/g, carotenoids 3.347 ± 0.006 mg/g, and 
ferric reducing antioxidant power about 0.186 ± 0.0004 
mg/mL that this data show that noni fruit has activity 
potential antioxidant [15].
Clinical Trials
This research was an experimental study 
using a double-blind randomized controlled trial 
design conducted at the H. Adam Malik General 
Hospital Medan, USU Pharmacy Laboratory, for 
extracting M. citrifolia and the Integrated Laboratory of 
Biochemistry-Biomolecular USU Faculty of Medicine 
for the examination of high-sensitivity CRP (hs-CRP) 
urine levels. This study was approved by the ethics 
committee Universitas Sumatera Utara regarding the 
implementation of health research no. 741/TGL/KEPK 
FK USU-RSUP HAM/2019.
The research sample was 56 female nursing 
health workers General Hospital. H. Adam Malik Medan 
who experienced OAB met the inclusion criteria that were 
willing to participate in the study and signed informed 
consent, women who were diagnosed with OAB based 
on OAB symptom scores (OABSS) and the results of 
urinalysis; and exclusion was consuming hormone 
replacement therapy, suffering from diabetes mellitus, 
suffering from UTIs, taking anti-depressant drugs, 
smoking, consuming alcohol, damaged samples, and 
withdrawing from research taken by the nonprobability 
method with consecutive sampling technique.
After obtaining approval from the Medical 
Faculty Ethics Committee University of North Sumatra 
and the Ethics Committee of RSUP H Adam Malik 
Medan, samples were taken at H Adam Malik General 
Hospital Medan. Sampling was done through interviews, 
filling out the OABSS questionnaire and urinalysis 
examination. The interview contained complaints of 
current illness, age, duration of menopause, and history 
of previous illnesses. Then, we measure womens 
height (m) and weight (kg) to determine of their body 
mass index. Urinalysis examination is then performed 
to rule out UTI. The urine that is taken is the middle 
portion of urine that is accommodated in a sterile urine 
pot. Then, the middle portion of urine was taken as 
much as 1 pot of urine for the examination of hs-CRP 
levels in the Integrated Laboratory of Biochemistry-
Biomolecular USU Faculty of Medicine. Group A: A 
group was given 5 mg of solifenacin drug capsules, 
one capsule daily for 30 days; then, blood and urine 
samples are examined. Group B: The group was given 
noni fruit extract capsules (M. citrifolia) at a dose of 500 
mg (8–16 mg/kg body weight), one capsule a day for 30 
days; then, the urine sample was examined.
Noni fruit extract is made by percolation using 
70% ethanol solvent and done in the pharmacology 
laboratory, faculty of pharmacy, Universitas Sumatera 
A - Basic Sciences Pharmacology
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Utara. A total of 8 kg of M. citrifolia powder was put into 
a closed vessel, soaked with 70% ethanol, left for 3 h, 
and protected from light, while occasionally stirring using 
a shaker. The results of the immersion are put into a 
percolator that has been pre-packaged, allowed to stand 
for 24 h. About 70% ethanol is supplied to the reservoir, 
add ethanol solution continuously until the color of ethanol 
is clear. All ethanol reservoirs are combined; then, the 
solution is concentrated so that a thick extract is obtained. 
Then, the thick extract was evaporated with a rotary 
evaporator at a temperature of 45–50°C, then dried with a 
freeze dryer to obtain a thick extract. Thick extracts were 
added with starch manihot and starch maydis in a ratio of 
1:1 to the sample, homogeneous using mortars and then 
dried using an oven with a temperature of 60°C for 24 h.
Data are processed and analyzed by the 
computerized system with statistical software. Data 
characteristics of the study sample were analyzed 
using descriptive statistics. Univariate data were urine 
hs-CRP levels. Data normality test is done by Shapiro–
Wilk test. To see the difference in average levels of 
urine hs-CRP, before and after administration of noni 
fruit extracts was done by t-dependent test if the data 
distribution was normally distributed or if the data 
distribution was not normally distributed, the median 
value was compared with the Mann–Whitney U-test.
To see the effect of noni on urinary CRP 
hs-CRP levels, the Wilcoxon Signed-Ranks Test was 
performed. Statistical significance test with CI 95% and 
a significant difference value p <0,05.
Results
In this study, patients did not experience 
significant side effects that no patients were dropped out.
Research subject characteristics
From Table 1 in Groups A and B of OAB 
sufferers, the majority of samples were aged 51–55 
years, 39.29 7% and 42.86% were already 2 years old 
at menopause, that is, 39.29% and 42.8% and were in 
the obese category weight, that is, 57.14% and 42.86%.
Urine hs-CRP and degree of OABSS before 
treatment
From Table 2, the urine hs-CRP levels in Group 
A are higher than those in Group B, where the hs-CRP 
level 8.69 ± 1.94 versus 8.30 ± 2.67 pq/mg was obtained. 
Based on statistical analysis, there were no significant 
differences in urine hs-CRP levels (p = 0.523) between 
Group A and Group B before treatment.
Table 2: hs-CRP levels in Groups A and B before treatment
Content/group N Mean SD Minimum Maximum p*
hs-CRP (mg/L)
Grp. A 28 8.69 1.94 4.94 12.80 0.503
Grp. B 28 8.31 2.67 1.78 14.60
*Mann–Whitney U-test.
Table 3 shows that the urine hs-CRP levels in 
severe OABSS are higher than moderate and mild OABSS, 
which is at urine hs-CRP levels obtained 9.16 ± 1.43 mg/L 
compared to 8.46 ± 2.30 mg/L and 8.39 ± 2.60 mg/L versus 
9.16 ± 1.43 mg/L. These results indicate an increase in the 
degree of OABSS in line with an increase in hs-CRP.
Table 3: hs-CRP levels for OABSS before treatment (n = 56)
Level OABSS hs-CRP (mg/L)
Mean ± SD
Mild (≤ 5) 8.39 ± 2.60
Moderate (6 – 11) 8.46 ± 2.30
Severe (≥ 12) 9.16 ± 1.43
Furthermore, observing the distribution of 
hs-CRP levels in both groups, the Saphiro–Wilk test 
was carried out because the sample size was <50, the 
data were not normally distributed.
In Table 4, these results indicate no significant 
difference (p > 0.05) of urine hs-CRP to the degree of 
OABSS between Group A and Group B before treatment.
Table 4: Differences in hs-CRP levels on OABSS before 
treatment
OABSS Group A (n = 28) Group B (n = 28) p*
Mild (≤ 5) n = 10 (35.71%) n = 9 (32.14%)
hs-CRP (mg/L) 8.49 ± 2.36 8.27 ± 2.99 0.624
Moderate (6–11) n = 16 (57.14%) n = 16 (57.14%)
hs-CRP (mg/L) 8.67 ± 1.79 8.26 ± 2.76 0.706
Severe (≥ 12) n = 2 (7.14%) n = 3 (10.71%)
hs-CRP (mg/L) 9.88 ± 0.74 8.67 ± 1.72 0.564
*<0,05
hs-CRP urine after treatment
In Table 5, hs-CRP levels in urine in Group B 
are lower than in Group A, that is, hs-CRP levels were 
4.47 ± 1.22 mg/L compared to 4.51 ± 1.54 mg/L.
Table 1: Subject characteristics
Characteristics Group 
A (n = 28) (%)
Group 
B (n =2 8) (%)
p*
Age (n, %) (years)
41–45 6 21.43 5 17.86
46–50 11 39.29 11 39.29 0.826
51–55 11 39.29 12 42.86
Menopause status (n, %)
Not menopause 7 25.00 6 21.43
Menopause 21 75.00 22 78.57
Menopause (n, %) (years)
1 4 14.29 3 10.71
2 11 39.29 12 42.86 
3 3 10.71 4 14.29 0.901
4 3 10.71 2 7.14
5 0 0.0 1 3.57
Body mass index (n, %)
Normoweight 0 0.0 4 14.30 
Overweight 12 42.86 12 42.86 0.116
Obese 16 57.14 12 42.86 
*<0,05
Figure 1: Differences in high-sensitivity C-reactive protein levels AQ6
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In Table 6, these results indicate no significant 
difference (p > 0.05) levels of hs-CRP in both mild and 
moderate OABSS between Group A and Group B after 
treatment.
Table 6: Differences in hs-CRP levels in OABSS after treatment
OABSS Group A (n=28) Group B (n=28) p*
Mild (≥ 5) n = 23 (82.14%) n = 24 (85.71%)
hs-CRP (mg/L) 4.33 ± 1.24 4.55 ± 1.24 0.663
Moderate ( 6–11) n = 5 (17.86%) n = 4 (14.29%)
hs-CRP (mg/L) 5.35 ± 2.55 4.01 ± 1.19 0.327
Severe (≥ 12) (n = 0) (n = 0)
*Mann–Whitney U-test.
The effect of M. citrifolia extract on hs-CRP 
OAB female urine
In Table 7, urine hs-CRP levels were lower 
after administration compared to before administration 
of solifenacin, which was 8.69 ± 1.94 pq/mg compared 
4.51 ± 1.54 pq/mg. From statistical analysis, hs-CRP 
levels of urine were found to be p < 0.001, p < 0.0001, 
and p < 0.0001. These results indicate a significant 
difference (p < 0.05) in hs-CRP levels after administration 
compared to before administration of solifenacin.
Table 7: Effect of solifenacin and noni fruit extract on hs-CRP 
levels (n=28)
Content Solifenacin p* Morinda citrifolia p*
Before After Before After
hs-CRP (mg/L) 8.69 ± 1.94 4.51 ± 1.54 <0.001 8.03 ± 2.66 4.47 ± 1.22 <0.0001
*Wilcoxon Test.
For the assessment of the effect of Noni extract 
versus solifenacin we can see the changes of hs-CRP 
levels of urine.
In table 8, we found that, the value of the effect 
of solifenacin is more significantly affect levels of hs-CRP 
urine than noni fruit extract (solfenacin effect size : 2,3, 
Noni fruit effect size : 1,72). From the data above, the 
value of the effect of solifenacin is more significantly 
affect levels of hs-CRP urine than noni fruit extract.
Table 8: Effect of noni fruit extract compared to solifenacin on 
changes in hs-CRP urine levels
Levels Before After Effect size
hs-CRP (mg/L)
Solifenacin 8.69 ± 1.94 4.51 ± 1.54 2,3
Noni fruit 8.03 ± 2.66 4.47 ± 1.22 1,72
The effect of M. citrifolia extract on female 
OAB
Table 9 shows that the majority of OABSS 
are in mild OABSS (85.71%), followed by moderate 
degree OABSS (14.29%). These results indicate that 
the administration of noni fruit extract has the same 
effect as giving solifenacin to a decrease in the degree 
of OAB in women.
Discussion
Changes in neurotransmitters and 
increased inflammation and oxidative stress in the 
bladder contribute to OAB symptoms in the elderly 
population [16]. Bladder inflammation also stimulates 
serum CRP levels in OAB men and women [17]. 
Besides that, obtained mediators of inflammatory 
PGE2 which are synthesized in muscle and 
bladder mucosa will affect normal urinary reflexes 
and pathological conditions such as mucosal 
damage [18], as well as a significant increase in 
serum CRP levels in patients with OAB by 1 83 ± 
2.30 mg/L. This data support the hypothesis of the 
bladder inflammation process in the pathophysiology 
of OAB [8].
Several questionnaire-based systems 
have been used to assess OAB and its treatment 
outcomes. Several scoring systems have been 
used, such as the OAB questionnaire, the patient 
perception of bladder condition, the primary OAB 
symptom questionnaire, OAB symptom composite 
score, urgency questionnaire, and OABSS. Chuang 
et al., in his study comparing several scoring systems 
to assess OAB patients, found that OABSS was not 
inferior to other questionnaires such as Urgency 
Severity Scale [19].
ROS is involved in the pathway that 
produces COX-2 expression in cells. The synthesis 
of PGs by cyclooxygenase (COX) depends on 
the peroxidase process. It is also known that 
lipoxygenase is activated by ROS. The first step in 
the arachidonic pathway is the release of arachidonic 
acid from the phospholipid membrane by the 
enzyme phospholipase A2. Arachidonic acid is then 
converted into eicosanoids through three pathways, 
namely, COX, lipoxygenase, and cytochrome P-450 
(cyt P450). Antioxidants and enzymes are able to 
limit the process of peroxidation, thereby inhibiting 
the availability of COX-2. It is known that noni juice 
has an anti-inflammatory effect, with its capacity 
to be able to inhibit COX activity, which can inhibit 
COX-1 by 32% and COX-2 by 25%. In another study, 
a decrease in anti-inflammatory TNF-α and IFN-NO, 
NO, and IL-17 after administration of noni fruit 
juice [20]. Wang et al. had a significant reduction in 
hs-CRP by 15.2% (p < 0.05) others after taking TNJ 
29.5 mL for 30 days [21].
Table 5: hs-CRP levels after treatment
Kadar/Group n Mean SD Minimum Maksimum p*
hs-CRP (mg/L)
Group A 28 4.51 1.54 2.15 9.89 0.993
Group B 28 4.47 1.22 2.56 7.36
*Mann–Whitney U-test.
Table 9: Differences in the effect of solifenacin and noni fruit 
extract on OABSS
OABSS Solifenacin Noni fruit
Before (n, %) After (n, %) Before (n, %) After (n, %)
Mild (≤ 5) 10 (35.71) 23 (82.14) 9 (32.14) 24 (85.71)
Moderate (6–11) 16 (57.14) 5 (17.86) 16 (57.14) 4 (14.29)
Severe (≥ 12) 2 (7.14) 0 (0.00) 3 (10.74) 0 (0.00)
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Conclusion
Noni (M. citrifolia) extract is proven to inhibit 
oxidative stress in urothelium by observing levels of 
hs-CRP urine in OAB women.
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